{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:38:22Z","timestamp":1793608702525,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107469","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T16:24:28Z","timestamp":1729355068000},"page":"107469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives"],"prefix":"10.1016","volume":"209","author":[{"given":"Jinlan","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxuan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Buerliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107469_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Addiction to oncogenes--the achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107469_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","article-title":"Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment","volume":"21","author":"Petroni","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107469_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107469_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.phrs.2024.107469_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.tibtech.2021.03.007","article-title":"Smart nucleic acids as future therapeutics","volume":"39","author":"Zhang","year":"2021","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.phrs.2024.107469_bib7","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107469_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107469_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","article-title":"Antibody-oligonucleotide conjugates enter the clinic","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2024.107469_bib14","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","article-title":"Antibody-oligonucleotide conjugates as therapeutic, imaging, and detection agents","volume":"30","author":"Dovgan","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2024.107469_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of oligonucleotides: efficiency with lipid conjugation and clinical outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2024.107469_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2024.107469_bib19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107469_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107469_bib21","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.3390\/cancers13195002","article-title":"Nucleic acid drugs-current status, issues, and expectations for exosomes","volume":"13","author":"Yamada","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107469_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cytogfr.2007.06.016","article-title":"The response of mammalian cells to double-stranded RNA","volume":"18","author":"Gantier","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib23","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1073\/pnas.0812317106","article-title":"Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth","volume":"106","author":"Cho","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/nat.2013.0463","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology","volume":"24","author":"Juliano","year":"2014","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7150\/thno.5743","article-title":"Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice","volume":"3","author":"Iversen","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2024.107469_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2024.107469_bib27","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1039\/b920362c","article-title":"RNA interference: a chemist\u2019s perspective","volume":"39","author":"Gaynor","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib28","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib29","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1021\/ja00332a054","article-title":"Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides","volume":"106","author":"Stec","year":"1984","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107469_bib30","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2024.107469_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2024.107469_bib33","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/pharmaceutics14112389","article-title":"Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology","volume":"14","author":"Amanat","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2024.107469_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2024.107469_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.phrs.2024.107469_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.phrs.2024.107469_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2217\/nnm.11.79","article-title":"In vivo biodistribution of nanoparticles","volume":"6","author":"Almeida","year":"2011","journal-title":"Nanomed"},{"key":"10.1016\/j.phrs.2024.107469_bib39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jconrel.2022.09.040","article-title":"Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy","volume":"351","author":"Lee","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2024.107469_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.cgt.7700337","article-title":"Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells","volume":"8","author":"Li","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/jacs.5b09974","article-title":"Emerging frontiers in drug delivery","volume":"138","author":"Tibbitt","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107469_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003601","article-title":"Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis","volume":"4","author":"Yao","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2024.107469_bib43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.canlet.2013.05.035","article-title":"PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth","volume":"338","author":"Su","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2024.107469_bib44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB\u2013siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib45","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-2017","article-title":"Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer","volume":"21","author":"B\u00e4umer","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107469_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/08820139.2017.1301466","article-title":"Variable heavy chain domain derived from a cell-penetrating anti-DNA monoclonal antibody for the intracellular delivery of biomolecules","volume":"46","author":"Im","year":"2017","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.phrs.2024.107469_bib47","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1093\/nar\/gkaa286","article-title":"Generation and validation of structurally defined antibody-siRNA conjugates","volume":"48","author":"Nanna","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211041453","article-title":"Cetuximab-siRNA conjugate linked through cationized gelatin knocks down KRAS G12C mutation in NSCLC sensitizing the cells toward gefitinib","volume":"20","author":"Sreedurgalakshmi","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2024.107469_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120940","article-title":"Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA","volume":"606","author":"Yu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2024.107469_bib50","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/acs.molpharmaceut.0c01001","article-title":"Nanobody-siRNA conjugates for targeted delivery of siRNA to cancer cells","volume":"18","author":"Zavoiura","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2024.107469_bib51","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1039\/D2SC01672A","article-title":"A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib52","article-title":"T cell-signaling-responsive conjugate of antibody with siRNA to overcome acquired resistance to anti-PD-1 immunotherapy","volume":"5","author":"Wang","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib53","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/cancers14030566","article-title":"Successful incorporation of exosome-capturing antibody-siRNA complexes into multiple myeloma cells and suppression of targeted mRNA transcripts","volume":"14","author":"Soma","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107469_bib54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2119\/molmed.2015.00210","article-title":"Novel targeted therapy for precursor B cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate","volume":"22","author":"Satake","year":"2016","journal-title":"Mol. Med."},{"key":"10.1016\/j.phrs.2024.107469_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.omtn.2018.04.004","article-title":"Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells","volume":"11","author":"Arnold","year":"2018","journal-title":"Mol. Ther\u00a0Nucleic Acids"},{"key":"10.1016\/j.phrs.2024.107469_bib56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/pharmaceutics12060545","article-title":"Development of antibody-oligonucleotide complexes for targeting exosomal MicroRNA","volume":"12","author":"Yamayoshi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2024.107469_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u201chigh-hanging fruit","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib58","doi-asserted-by":"crossref","first-page":"16724","DOI":"10.1002\/jcp.28490","article-title":"Antibody-drug therapeutic conjugates: potential of antibody-siRNAs in cancer therapy","volume":"234","author":"Yarian","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2024.107469_bib59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107469_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd2241","article-title":"Development trends for monoclonal antibody cancer therapeutics","volume":"6","author":"Reichert","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107469_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/0929867324666170817152554","article-title":"Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations","volume":"26","author":"Kholodenko","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107469_bib65","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.copbio.2011.03.008","article-title":"Protein transduction domain delivery of therapeutic macromolecules","volume":"22","author":"Van Den Berg","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.phrs.2024.107469_bib66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jmr.2394","article-title":"Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition","volume":"27","author":"Van Regenmortel","year":"2014","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.phrs.2024.107469_bib67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molimm.2023.02.005","article-title":"Polyspecificity - an emerging trend in the development of clinical antibodies","volume":"155","author":"Sandeep","year":"2023","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2024.107469_bib68","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107469_bib69","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107469_bib70","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107469_bib71","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.62642","article-title":"Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2024.107469_bib72","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","volume":"9","author":"Gagliardi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2024.107469_bib73","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/bib\/bby054","article-title":"Trends in the development of miRNA bioinformatics tools","volume":"20","author":"Chen","year":"2019","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.phrs.2024.107469_bib74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107469_bib75","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2024.107469_bib76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib77","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","article-title":"Bioconjugated oligonucleotides: recent developments and therapeutic applications","volume":"30","author":"Benizri","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2024.107469_bib78","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1016\/j.biomaterials.2013.07.019","article-title":"Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery","volume":"34","author":"Chan","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2024.107469_bib79","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1039\/D1CB00038A","article-title":"Sulfur modification in natural RNA and therapeutic oligonucleotides","volume":"2","author":"Zheng","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107469_bib80","doi-asserted-by":"crossref","first-page":"11542","DOI":"10.1073\/pnas.1108535108","article-title":"Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs)","volume":"108","author":"Yanai","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib81","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib82","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2024.107469_bib83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-020-00225-0","article-title":"Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer","volume":"8","author":"Xue","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2024.107469_bib84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cbpa.2019.06.006","article-title":"Peptide nucleic acid (PNA) and its applications in chemical biology, diagnostics, and therapeutics","volume":"52","author":"Saarbach","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107469_bib85","doi-asserted-by":"crossref","first-page":"4.30.1","DOI":"10.1002\/cpnc.21","article-title":"Using morpholinos to control gene expression","volume":"68","author":"Moulton","year":"2017","journal-title":"Curr. Protoc. Nucleic Acid. Chem."},{"key":"10.1016\/j.phrs.2024.107469_bib86","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"Markati","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2024.107469_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300077","article-title":"Chemical biology approaches toward precise structure control of IgG-based antibody-oligonucleotide conjugates","volume":"24","author":"Shen","year":"2023","journal-title":"ChemBioChem"},{"key":"10.1016\/j.phrs.2024.107469_bib88","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1073\/pnas.0608491104","article-title":"Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1","volume":"104","author":"Peer","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib89","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/cb200176v","article-title":"Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA","volume":"6","author":"Ma","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107469_bib90","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/mp800194y","article-title":"Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology","volume":"6","author":"Xia","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2024.107469_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009463","article-title":"Novel siRNA delivery system to target podocytes in vivo","volume":"5","author":"Hauser","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2024.107469_bib92","doi-asserted-by":"crossref","first-page":"287a","DOI":"10.1016\/j.bpj.2016.11.1557","article-title":"Molecular dynamics study for streptavidin mutant with\/without biotin analog","volume":"112","author":"Shinoda","year":"2017","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2024.107469_bib93","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1021\/ja4059525","article-title":"Site-specific antibody-polymer conjugates for siRNA delivery","volume":"135","author":"Lu","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107469_bib94","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/mabs.19449","article-title":"Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates","volume":"4","author":"Acchione","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.phrs.2024.107469_bib95","first-page":"56","article-title":"More useful maleimide compounds for the conjugation of fab to\u00a0horse peroxidase thiol groups hinge","volume":"6","author":"Hashida","year":"1984","journal-title":"J. Appl. Biochem."},{"key":"10.1016\/j.phrs.2024.107469_bib96","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1124\/pharmrev.121.000499","article-title":"New technologies bloom together for bettering cancer drug conjugates","volume":"74","author":"Jin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature01451","article-title":"Regulated portals of entry into the cell","volume":"422","author":"Conner","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107469_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.phrs.2024.107469_bib99","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107469_bib101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.phrs.2024.107469_bib102","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib103","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/nar\/19.5.1113","article-title":"Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism","volume":"19","author":"Boiziau","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2024.107469_bib104","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2024.107469_bib105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/nar\/29.6.1293","article-title":"Fully modified 2\u2019 MOE oligonucleotides redirect polyadenylation","volume":"29","author":"Vickers","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib106","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/d41573-020-00078-0","article-title":"RNA therapeutics on the rise","volume":"19","author":"Wang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107469_bib107","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1126\/science.1062039","article-title":"A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans","volume":"293","author":"Knight","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107469_bib108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107469_bib109","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature09092","article-title":"A dicer-independent miRNA biogenesis pathway that requires Ago catalysis","volume":"465","author":"Cheloufi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107469_bib110","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1093\/nar\/gkt361","article-title":"Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing","volume":"41","author":"Lee","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib111","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2005.08.044","article-title":"Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes","volume":"123","author":"Matranga","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107469_bib112","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2005.10.020","article-title":"Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation","volume":"123","author":"Rand","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107469_bib113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1101\/sqb.2006.71.042","article-title":"Structure of Dicer and mechanistic implications for RNAi","volume":"71","author":"MacRAE","year":"2006","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.phrs.2024.107469_bib114","doi-asserted-by":"crossref","first-page":"26.1.1","DOI":"10.1002\/0471142727.mb2601s112","article-title":"RNA interference and microrna-mediated silencing","volume":"112","author":"Fischer","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107469_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114269","article-title":"The paradigm of miRNA and siRNA influence in Oral-biome","volume":"159","author":"Sinha","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2024.107469_bib116","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/bit.27302","article-title":"Detection and destruction of HER2-positive cancer cells by Ultra Quenchbody-siRNA complex","volume":"117","author":"Dong","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.phrs.2024.107469_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.39","article-title":"Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies","volume":"1","author":"Schneider","year":"2012","journal-title":"Mol. Ther Nucleic Acids"},{"key":"10.1016\/j.phrs.2024.107469_bib118","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2024.107469_bib119","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.phrs.2024.107469_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2024.107469_bib121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1261\/rna5160904","article-title":"Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs)","volume":"10","author":"Persengiev","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.phrs.2024.107469_bib122","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1093\/nar\/gki762","article-title":"siRNA-mediated off-target gene silencing triggered by a 7 nt complementation","volume":"33","author":"Lin","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2024.107469_bib123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.08.004","article-title":"Functional peptides for siRNA delivery","volume":"110\u2013111","author":"Tai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib124","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab540","article-title":"Protein-RNA interaction prediction with deep learning: structure matters","volume":"23","author":"Wei","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.phrs.2024.107469_bib125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/ijbs.79328","article-title":"Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy","volume":"19","author":"Qiu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2024.107469_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2024.107469_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."}],"updated-by":[{"DOI":"10.1016\/j.phrs.2024.107513","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:55:00Z","timestamp":1734569700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824004146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":127,"alternative-id":["S1043661824004146"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107469","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107469"}}